Precision Medicine in Prostate Cancer: The Role of Molecular Diagnostics and Targeted Therapies

Prostate cancer is a major health problem in the world, and it has been complicated by the fact that the illness is quite heterogeneous. In the past, the use of PSA testing and histopathological grading has been constrained by failure to reliably distinguish between indolent and aggressive cancer. In this review, the concept of a fundamental change in the field of prostate cancer treatment, facilitated by the development of molecular diagnostics, is discussed. We discuss how genomic classifiers, epigenetic assays, and commercially available tests of biomarkers are being integrated to make risk stratification much more precise and tailored treatment decisions. Also, the stage of imaging, especially PSMA-targeted PET, breakthrough is transforming the accuracy of staging. Dynamic monitoring of tumor evolution has now been made possible by the introduction of liquid biopses, which can be used to study tumor-derived signals in the blood in a non-invasive manner. It is these diagnostic advances that are directly leading to a new generation of therapies that are targeted such as PSMA-directed radioligand therapy and drugs that target molecular weaknesses in cancer cells. Although this is a promising development, to achieve the full potential of precision medicine, the various obstacles, including tumor evolution, and clinically-implementation obstacles must be overcome. It is important to note that more efforts should be put to perfect these tools and strategies in the long run to enhance the results and life of men who have this disease.